734-936-8000 - Service Desk | Request Support

9th Annual Michigan Medicine Liver Round-Up (On-Demand)

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials
Release Date: Sat, 1/1/22
Termination Date: Sun, 12/31/23
Credits: 2
The University of Michigan Transplant Center is pleased to offer our 9th Annual Michigan Medicine Liver Round-Up as a live webinar for health care professionals on advances in clinical hepatology.

Educational Planning Team

Educational Planner
Robert J Fontana, MD

Christopher J Sonnenday, MD
Julia Huang, RN, BSN, CCTC

Activity Coordinators
Stacy Brand, MBA
Michele Cromer
Disclosure: There are no relevant financial relationships to disclose for this activity.

To participate in this CME activity:

  • Login to MiCME 
    • U-M employees with Level-1 credentials should use the University of MIchigan Login.
    • Non-UM employees should use the Non-UM Login.
    • New, non-UM employees should create a new account.
  • Complete your Profile, including the Board Reporting section if you are board-certified and wish to receive MOC credit. Return to the activity page.
  • Click on the Enroll/Purchase button above to pay and review the educational content.
  • The CME activity ends once the post-test is passed and the evaluation is complete. 
  • At this point, you may view/print your certificate.

Educational Objectives: This activity address new developments in the management of Hepatorenal syndrome.

Participants will be able to identify:
- patients who are eligible for liver transplantation
- candidates for treatment for HRS
- candidates for checkpoint inhibitors and VEGF inhibitors for HCC
- risks and benefits of biological therapies for HCC

Participants will be able to diagnose:
- Hepatorenal syndrome
- Patients with liver failure
Target Audience:

This activity is appropriate for:
House Officers, Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians

In the fields of:
Family Medicine, Gastroenterology, General Medicine, Hepatology, Internal Medicine, Primary Care, Transplant Surgery

Accreditation and Credit Designation:

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC credit.

Additional Info: Bibliographic Resources

1. Finn RS, et al. Atezolizumab plus bevacizumab in unresectable HCC. NEJM 2020; 382: 1894-1905.
2. Diagnosis, Staging, and Management of HCC: 2018 Practice Guidance by the AASLD. Hepatology 2018; 68: 723-750.
3. Introduction to the Revised AASLD Practice guideline on Management of Adults with ascites due to cirrhosis, 2012. Hepatology 2013: 57: 1650- 1676

Credits available:

ABIM MOC Part II: 2.00
AMA PRA Category 1: 2.00
Participation: 2.00